论文部分内容阅读
肿瘤的过继免疫治疗中新近发展起来的CIK细胞治疗在近几年的恶性肿瘤治疗领域逐渐成为国内外关注的焦点。CIK细胞是一种免疫效应细胞,经多种细胞因子诱导后具有比LAK细胞更快的增殖速度,同时兼具T淋巴细胞强大的杀瘤活性和NK细胞的非MHC限制性。自上世纪80年代发现这种细胞起,人们对于CIK细胞生物学特征的认识一直在不断的更新,目前以CIK细胞为主治疗恶性肿瘤的技术已经在国内临床开展,并有望成为肿瘤综合治疗研究的新方向。
The newly developed CIK cell therapy in the adoptive immunotherapy of tumors has gradually become the focus of attention at home and abroad in the field of malignant tumor therapy in recent years. CIK cells are immune effector cells that are induced by a variety of cytokines to proliferate faster than LAK cells and possess both powerful tumoricidal activity of T lymphocytes and non-MHC-restricted NK cells. Since the discovery of such cells in the 1980s, people’s understanding of the biological characteristics of CIK cells has been constantly updated. At present, the technology of treating malignant tumors mainly based on CIK cells has been clinically developed in China and is expected to become a comprehensive treatment of cancer New direction.